Target intelligence / Profile preview

Solute carrier family 35 member B2 (SLC35B2)

Target
SLC35B2
Molecular classification
Transporter, Solute carrier family
01

Overview

Solute carrier family 35 member B2 (SLC35B2) is a transporter protein located in the Golgi and endoplasmic reticulum membranes that mediates the import of 3'-phosphoadenosine 5'-phosphosulfate (PAPS), the universal sulfuryl donor, from the cytosol into the Golgi lumen. This process is essential for the sulfation of glycans, glycoproteins, and glycolipids—a key modification affecting protein and extracellular matrix function. Loss-of-function mutations in SLC35B2 cause inherited disorders of sulfation such as hypomyelinating leukodystrophy and skeletal dysplasia. SLC35B2 is also required for the correct sulfation of cell-surface heparan sulfate proteoglycans, which regulate cellular recognition, viral entry, and growth factor signaling. There are no approved drugs directly targeting SLC35B2, and broad inhibition raises safety concerns due to the global impact on sulfation pathways.

Other names
Adenosine 3'-phospho 5'-phosphosulfate transporter 1PAPST1PSEC0149UGTrel4PAPS transporter 1Putative MAPK-activating protein PM15Putative NF-kappa-B-activating protein 48SLLHLD26
02

Mechanism of action

Inhibition or loss-of-function would reduce cellular sulfation by impairing PAPS transport into the Golgi, affecting the synthesis of sulfated proteins and glycosaminoglycans.

03

Biological functions

Transports 3'-phosphoadenosine 5'-phosphosulfate (PAPS) from cytosol to the Golgi lumenSupports sulfation of glycoproteins, proteoglycans, and glycolipidsCritical in glycosaminoglycan metabolism
04

Disease associations

Leukodystrophy, hypomyelinating, 26, with chondrodysplasiaPrimary bone dysplasia with multiple joint dislocationsOther congenital disorders of sulfation
05

Safety considerations

Disruption causes developmental disorders related to impaired sulfation, particularly lung, brain, and bone pathologyBroad suppression likely to have widespread effects on protein and glycan modification
06

Biomarkers

Loss-of-function variants are associated with hypomyelinating leukodystrophySulfation levels of glycoproteins or proteoglycans (research context)

Beyond the preview

Go deeper on Solute carrier family 35 member B2 (SLC35B2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 35 member B2 (SLC35B2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call